Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05541822 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
A Phase 2 study of Advanced Solid Tumors, sponsored by Abion.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
- 20
- Study locations
NCT05541822 is a Phase 2 study of Advanced Solid Tumors that is actively recruiting participants, run by Abion. The registered enrollment target is 178 participants, below the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05541822, a Phase 2 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Abion.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
- 20
- Study locations
Study Summary
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.
Conditions Studied
Interventions
- DRUG Lazertinib
- DRUG Vabametkib
Study Locations (20)
Other
- Chungbuk National University Hospital - Cheongju-si
- Gachon University Gil Medical Center - Incheon
- Gyeongsang National University Hospital - Jinju
- Seoul National University Bundang Hospital - Seongnam-si
- Kangbuk Samsung Hospital - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
- The Catholic University of Korea, Seoul St Mary's Hospitals - Seoul
- The Catholic University of Korea St Vincents Hospital - Suwon
- China Medical University Hospital - Taichung
- National Cheng Kung University Hospital - Tainan
Seoul
- Boramae Medical Center - Dongjak
- Korea University Anam Hospital - Seoul
- Severance Hospital - Sinchon-dong
Florida
- Cancer Care of North Florida, PA (Lake City Cancer Care, LLC) - Medical Oncology - Lake City
- Mid Florida Center - Orange City
Gyeonggi-do
- National Cancer Center - Goyang-si
- Ajou University Hospital - Suwon
Michigan
- The Henry Ford Cancer Institute - Detroit
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05541822
The ClinicalTrials.gov registry entry for NCT05541822 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (10% lower). The listed sponsor is Abion, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Lazertinib is the first listed.
NCT05541822 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Seoul, Florida.
Frequently Asked Questions
What is clinical trial NCT05541822 about?
NCT05541822 is a clinical study titled "To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation". ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.
What is the current status of trial NCT05541822?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2023-01-17. Estimated completion is 2029-02.
What conditions does trial NCT05541822 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT05541822?
The interventions under investigation include: Lazertinib (DRUG), Vabametkib (DRUG).
Who is sponsoring clinical trial NCT05541822?
This trial is sponsored by Abion, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05541822 being conducted?
This trial has 20 study locations across Florida, Michigan, Texas, Gyeonggi-do, Seoul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
RECRUITING · Phase 2
-
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RECRUITING · Phase 2
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
COMPLETED · Phase 2
-
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.